---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-131739"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:24:02.055867+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# 4DMT appoints CFO Kristian Humer as Principal Accounting Officer

## Summary
- Appointment effective March 25, 2026; Humer succeeds Ashoo Gupta.
- Humer continues as CFO and Principal Financial Officer (role since Nov 2025).
- Prior roles include CFO at Foghorn Therapeutics (Apr 2024–Nov 2025) and Viridian Therapeutics.
- Gupta remains Vice President, Finance and Controller of the company.

## SEC filing metadata
- accession: 0001193125-26-131739
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526131739/0001193125-26-131739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526131739/fdmt-20260325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-131739
- JSON: https://secwatch.observer/filing/0001193125-26-131739.json
- Plain text: https://secwatch.observer/filing/0001193125-26-131739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.